REVEAL GENOMICS® HER2DX® Genomic Test to Be Validated in Pivotal ECOG-ACRIN CompassHER2 pCR Trial in HER2+ Breast Cancer

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Genetics

Clinical Trials

Oncology

REVEAL GENOMICS, S.L.

More Like This

HER2DX studies presented at ASCO.

ASCO 2025: REVEAL GENOMICS Unveils New HER2DX Data From 800+ Patients

Groundbreaking Study Confirms Clinical Decision Impact of HER2DX® Genomic Assay in Early-Stage HER2-Positive Breast Cancer

Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer

SABCS 2025: REVEAL GENOMICS Presents Major Advance in Predicting Brain Metastasis in HER2+ Breast Cancer

DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved

Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024

The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences’ Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients

New Data Highlight the Positive Impact of Exact Sciences’ Oncotype DX® Test on Patient Care and Healthcare Efficiency